Organization
Leeds Teaching Hospitals NHS Trust
1 clinical trial
5 abstracts
Abstract
The clinical utility of plasma cell-free DNA (cfDNA) in NET-02: Randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).Org: CRUK Manchester Institute, Leeds Institute of Clinical Trials Research, Newcastle Hospital NHS Foundation Trust, Leeds Teaching Hospitals NHS Trust, CRUK Cancer Biomarker Centre,
Clinical trial
An Investigator-initiated Double-blind, Parallel-group Randomised Controlled Trial of GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA Using Clinical and Whole Body MRI Outcomes: the GOLMePsA Study.Status: Completed, Estimated PCD: 2023-07-01
Abstract
SMALL: Open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer—A UK phase III randomised multi-centre trial.Org: Queen's University Belfast, University of Cambridge, University of Oxford, Western General Hospital, University of Birmingham,
Abstract
Exploring the radiological differences of lymph nodes between mismatch repair deficient and mismatch repair proficient colon cancer.Org: University of Leeds, Leeds Teaching Hospitals NHS Trust,
Abstract
BIOSAMPLES FROM VEDOSS PATIENTS SHOW CLASSIC PATHOLOGICAL SIGNS OF SCLERODERMA:OPPORTUNITY FOR A BIOLOGICAL DIAGNOSIS OF DISEASEOrg: University of Leeds, LIRMM, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom,
Abstract
BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WHO WERE RESPONDERS AT WEEK 16: RESULTS FROM BE OPTIMAL, A PHASE 3, ACTIVE-REFERENCE STUDYOrg: UCB Pharma, ASST Gaetano Pini-CTO, Dept of Rheumatology, Milan, Italy, University of Milano, European Institute of Oncology, Division of Early Drug Development, Centre for Therapeutic Innovation, University of Bath,